Literature DB >> 33031030

Development of MicroRNA-Based Therapeutics for Vascular Disease.

Kia J Jones1, Charles D Searles1.   

Abstract

Entities:  

Keywords:  Editorials; RNAi-based therapeutics; angiogenesis inhibitors; arteriovenous malformation; gene expression; microRNA

Mesh：

Substances：

Year:  2020        PMID： 33031030      PMCID： PMC7934353          DOI： 10.1161/CIRCRESAHA.120.317999

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  15 in total

1.  Distributions of local oxygen saturation and its response to changes of mean arterial blood pressure in the cerebral cortex adjacent to arteriovenous malformations.

Authors:  B Meyer; C Schaller; C Frenkel; B Ebeling; J Schramm
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

2.  Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells.

Authors:  Carmen Doebele; Angelika Bonauer; Ariane Fischer; Alexander Scholz; Yvonne Reiss; Carmen Urbich; Wolf-Karsten Hofmann; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

Review 3.  Evaluation of intranasal delivery route of drug administration for brain targeting.

Authors:  Franciska Erdő; Luca Anna Bors; Dániel Farkas; Ágnes Bajza; Sveinbjörn Gizurarson
Journal:  Brain Res Bull       Date:  2018-10-25       Impact factor: 4.077

4.  Increased endothelial progenitor cells and vasculogenic factors in higher-staged arteriovenous malformations.

Authors:  Lingge Lu; Joyce Bischoff; John B Mulliken; Diane R Bielenberg; Steven J Fishman; Arin K Greene
Journal:  Plast Reconstr Surg       Date:  2011-10       Impact factor: 4.730

5.  miR-18a Inhibits BMP4 and HIF-1α Normalizing Brain Arteriovenous Malformations.

Authors:  Nagore I Marín-Ramos; Thu Zan Thein; Ketan B Ghaghada; Thomas C Chen; Steven L Giannotta; Florence M Hofman
Journal:  Circ Res       Date:  2020-08-05       Impact factor: 17.367

6.  Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes.

Authors:  Changchun Xiao; Lakshmi Srinivasan; Dinis Pedro Calado; Heide Christine Patterson; Baochun Zhang; Jing Wang; Joel M Henderson; Jeffrey L Kutok; Klaus Rajewsky
Journal:  Nat Immunol       Date:  2008-03-09       Impact factor: 25.606

Review 7.  MicroRNAs: target recognition and regulatory functions.

Authors:  David P Bartel
Journal:  Cell       Date:  2009-01-23       Impact factor: 41.582

Review 8.  Pharmacomodulation of microRNA Expression in Neurocognitive Diseases: Obstacles and Future Opportunities.

Authors:  Viorel Simion; Wissem Deraredj Nadim; Helene Benedetti; Chantal Pichon; Severine Morisset-Lopez; Patrick Baril
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

9.  How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market.

Authors:  E Bonneau; B Neveu; E Kostantin; G J Tsongalis; V De Guire
Journal:  EJIFCC       Date:  2019-06-24

10.  Argonaute-2 promotes miR-18a entry in human brain endothelial cells.

Authors:  Raquel Ferreira; Tiago Santos; Arun Amar; Alex Gong; Thomas C Chen; Stanley M Tahara; Steven L Giannotta; Florence M Hofman
Journal:  J Am Heart Assoc       Date:  2014-05-16       Impact factor: 5.501
View more
  1 in total

1.  MicroRNA regulatory networks associated with abnormal muscle repair in survivors of critical illness.

Authors:  Christopher J Walsh; Carlos Escudero King; Muskan Gupta; Pamela J Plant; Margaret J Herridge; Sunita Mathur; Pingzhao Hu; Judy Correa; Sameen Ahmed; Anne Bigot; Claudia C Dos Santos; Jane Batt
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-01-28       Impact factor: 12.910
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.